Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* To reduce the thrombotic cardiovascular events (e.g., cardiovascular death, myocardial infarction, stroke) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **History of MI (>= 1 year post-MI):**
* **Maintenance Dose:** 60 mg orally twice daily. This indication requires ongoing treatment for secondary prevention after at least 1 year of dual antiplatelet therapy (DAPT) in ACS patients.
## Pediatric Dosing
* Dosing for pediatric patients is not established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is generally recommended. However, caution is advised in severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is generally recommended. However, ticagrelor has not been studied in patients with severe hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke when used in patients with ACS.
* Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, nefazodone).
## Adverse Effects
* **Most Common:** Bleeding (including fatal bleeding), dyspnea, bradycardia.
* **Serious:** Severe bleeding, ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with CYP3A4 substrates may increase exposure of these drugs (e.g., simvastatin, atorvastatin). Limit statin dose where appropriate.
* **Strong CYP3A4 Inducers:** May decrease ticagrelor exposure and efficacy (e.g., rifampin, carbamazepine, phenytoin).
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution and monitor closely. Aspirin is generally co-administered.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor heart rate for symptomatic bradycardia.
* Assess for dyspnea.
## Clinical Pearls
* Ticagrelor should be taken for at least 12 months in ACS patients, regardless of whether they are treated invasively or conservatively.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If ticagrelor must be discontinued due to bleeding or other concerns, consider the risks and benefits of continuing or restarting another antiplatelet agent.
* Avoid concomitant use with strong CYP3A4 inhibitors.
* Ticagrelor is a reversible inhibitor, unlike clopidogrel.
* Dyspnea is a common side effect and may be unrelated to cardiac causes.
***
**Disclaimer:** This information is intended for educational purposes and does not substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for any medical decisions.
